Database : MEDLINE
Search on : Neuromyelitis and Optica [Words]
References found : 3178 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 318 go to page                         

  1 / 3178 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29523094
[Au] Autor:Alroughani R; Boyko A
[Ad] Address:Division of Neurology, Department of Medicine, Amiri Hospital, Arabian Gulf Street, 13041, Sharq, Kuwait. alroughani@gmail.com.
[Ti] Title:Pediatric multiple sclerosis: a review.
[So] Source:BMC Neurol;18(1):27, 2018 Mar 09.
[Is] ISSN:1471-2377
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Pediatric-onset multiple sclerosis (POMS) prevalence and incidence rates are increasing globally. No disease-modifying therapy are approved for MS pediatric population. Hence, we aim to review the literature on POMS to guide treating physicians on the current understanding of diagnosis and management of pediatric MS. METHODS: The authors performed a literature search and reviewed the current understanding on risk factors and disease parameters in order to discuss the challenges in assessing and implementing diagnosis and therapy in clinical practice. RESULTS: The revised International Pediatric MS group diagnostic criteria improved the accuracy of diagnosis. Identification of red flags and mimickers (e.g. acute disseminated encephalomyelitis and neuromyelitis optica) are vital before establishing a definitive diagnosis. Possible etiology and mechanisms including both environmental and genetic risk factors are highlighted. Pediatric MS patients tend to have active inflammatory disease course with a tendency to have brainstem / cerebellar presentations at onset. Due to efficient repair mechanisms at early life, pediatric MS patients tend to have longer time to reach EDSS 6 but reach it at earlier age. Although no therapeutic randomized clinical trials were conducted in pediatric cohorts, open-label multi-center studies reported efficacy and safety results with beta interferons, glatiramer acetate and natalizumab in similar adult cohorts. Several randomized clinical trials assessing the efficacy and safety of oral disease-modifying therapies are ongoing in pediatric MS patients. CONCLUSION: Pediatric MS has been increasingly recognized to have a more inflammatory course with frequent infratentorial presentations at onset, which would have important implications in the future management of pediatric cohorts while awaiting the results of ongoing clinical trials.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:In-Process
[do] DOI:10.1186/s12883-018-1026-3

  2 / 3178 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29521337
[Au] Autor:Geraldes R; Ciccarelli O; Barkhof F; De Stefano N; Enzinger C; Filippi M; Hofer M; Paul F; Preziosa P; Rovira A; DeLuca GC; Kappos L; Yousry T; Fazekas F; Frederiksen J; Gasperini C; Sastre-Garriga J; Evangelou N; Palace J; MAGNIMS study group
[Ad] Address:Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.
[Ti] Title:The current role of MRI in differentiating multiple sclerosis from its imaging mimics.
[So] Source:Nat Rev Neurol;, 2018 Mar 09.
[Is] ISSN:1759-4766
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:MRI red flags proposed over a decade ago by the European Magnetic Resonance Network in MS (MAGNIMS) have guided clinicians in the diagnosis of multiple sclerosis (MS). However, the past 10 years have seen increased recognition that vascular disease can coexist and possibly interact with MS, improvements in the reliability of ways to differentiate MS from novel antibody-mediated CNS disorders (such as anti-aquaporin-4 antibody and myelin-oligodendrocyte glycoprotein antibody-associated diseases) and advances in MRI techniques. In this Review, MAGNIMS updates the imaging features that differentiate the most common mimics of MS, particularly age-related cerebrovascular disease and neuromyelitis optica, from MS itself. We also provide a pragmatic summary of the clinically useful MRI features that distinguish MS from its mimics and discuss the future of nonconventional techniques that have identified promising disease-specific features.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1038/nrneurol.2018.14

  3 / 3178 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29519720
[Au] Autor:Bo M; Niegowska M; Arru G; Sechi E; Mariotto S; Mancinelli C; Farinazzo A; Alberti D; Gajofatto A; Ferrari S; Capra R; Monaco S; Sechi G; Sechi LA
[Ad] Address:Department of Biomedical Sciences, University of Sassari, Viale San Pietro 43b, 07100 Sassari, Italy.
[Ti] Title:Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder.
[So] Source:J Neuroimmunol;, 2018 Feb 28.
[Is] ISSN:1872-8421
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Epstein-Barr virus (EBV) is the main environmental agent associated to neuromyelitis optica spectrum disorder (NMOSD). Following to studies reporting an increased prevalence of antibodies against peptides derived from Mycobacterium avium subsp. paratuberculosis (MAP) homologous to EBV and human epitopes (MBP , IRF5 ) in multiple sclerosis (MS), we investigated whether seroreactivity to these antigens display a NMOSD-specific pattern. The sera of 34 NMOSD patients showed elevated levels of antibodies against MAP and MBP compared to healthy controls (44% vs. 5%, p < 0.0002 and 50% vs. 2%, p < 0.0001, respectively), while, unlike in MS, responsiveness to EBV was similar.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher

  4 / 3178 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29443442
[Au] Autor:Wong YYM; Hacohen Y; Armangue T; Wassmer E; Verhelst H; Hemingway C; van Pelt ED; Catsman-Berrevoets CE; Hintzen RQ; Deiva K; Lim MJ; Rostsy K; Neuteboom RF
[Ad] Address:Department of Neurology, Erasmus MC, Rotterdam, The Netherlands.
[Ti] Title:Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome.
[So] Source:Eur J Neurol;, 2018 Feb 14.
[Is] ISSN:1468-1331
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND AND PURPOSE: Acute disseminated encephalomyelitis followed by optic neuritis (ADEM-ON) is a rare demyelinating syndrome that is different from multiple sclerosis and neuromyelitis optica spectrum disorder. The aim of this study was to describe the disease course, treatment response and outcome of children with ADEM-ON. METHODS: Children of <18years of age were identified from six countries of the EU Paediatric Demyelinating Disease Consortium. Patients fulfilled the diagnostic criteria for ADEM followed by at least one ON. Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies were tested in all patients. RESULTS: In this study of 17 patients (nine boys) with ADEM-ON, anti-myelin oligodendrocyte glycoprotein (MOG) antibodies were identified in 16 patients. Age at onset was 6.1years (interquartile range, 5.1-9.2years). Twelve patients received oral prednisolone and 10 received maintenance immunosuppression (e.g. azathioprine, intravenous immunoglobulins, Rituximab). During a follow-up of 5.3years (interquartile range, 1.8-10.2years), 54 relapses occurred with a median of 3 relapses per patient (range, 1-9 per patient). Patients relapsed on all treatments but no relapses occurred on a prednisolone dose >10mg/day. Visual and cognitive residual deficits were common in this group. CONCLUSIONS: Acute disseminated encephalomyelitis followed by optic neuritis is an anti-MOG antibody-associated relapsing disorder that can have a heterogeneous disease course. Patients were refractory for maintenance immunosuppression and appeared to be corticosteroid-dependent. Further international collaborations are now required to unify guidelines in this difficult-to-manage group of patients.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1111/ene.13602

  5 / 3178 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29428821
[Au] Autor:Tradtrantip L; Felix CM; Spirig R; Morelli AB; Verkman AS
[Ad] Address:Departments of Medicine and Physiology, University of California, San Francisco, CA, USA.
[Ti] Title:Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental invitro and rat models of neuromyelitis optica.
[So] Source:Neuropharmacology;133:345-353, 2018 Feb 08.
[Is] ISSN:1873-7064
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Intravenous human immunoglobulin G (IVIG) may have therapeutic benefit in neuromyelitis optica spectrum disorders (herein called NMO), in part because of the anti-inflammatory properties of the IgG Fc region. Here, we evaluated recombinant Fc hexamers consisting of the IgM -tailpiece fused with the Fc region of human IgG1. Invitro, the Fc hexamers prevented cytotoxicity in aquaporin-4 (AQP4) expressing cells and in rat spinal cord slice cultures exposed to NMO anti-AQP4 autoantibody (AQP4-IgG) and complement, with >500-fold greater potency than IVIG or monomeric Fc fragments. Fc hexamers at low concentration also prevented antibody-dependent cellular cytotoxicity produced by AQP4-IgG and natural killer cells. Serum from rats administered a single intravenous dose of Fc hexamers at 50 mg/kg taken at 8 h did not produce complement-dependent cytotoxicity when added to AQP4-IgG-treated AQP4-expressing cell cultures. In an experimental rat model of NMO produced by intracerebral injection of AQP4-IgG, Fc hexamers at 50 mg/kg administered before and at 12 h after AQP4-IgG fully prevented astrocyte injury, complement activation, inflammation and demyelination. These results support the potential therapeutic utility of recombinant IgG1 Fc hexamers in AQP4-IgG seropositive NMO.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher

  6 / 3178 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29517664
[Au] Autor:Chi LM; Gao Y; Nan GX
[Ad] Address:China-Japan Union Hospital of Jilin University, Changchun City, Jilin Province, China.
[Ti] Title:A case report of neuromyelitis optica spectrum disorder with peripheral neuropathy as the first episode.
[So] Source:Medicine (Baltimore);97(10):e0059, 2018 Mar.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Neuromyelitis optica spectrum disorders (NMOSDs) represent recurrent autoimmune diseases, generally beginning with optic nerve neuritis or acute transverse myelitis. PATIENT CONCERNS: A 57-year-old male with long-term alcohol intake was hospitalized because of limb numbness. EMG examination showed the peripheral sensory nerve was in demyelination and an axonal injury was found. His symptoms could not be improved by vitamin B injection but were later significantly attenuated by dexamethasone treatment. Four months later, symptoms of optic neuritis in the left eye appeared, and 6 months later he exhibited peripheral neuropathy with acute myelitis. DIAGNOSES: He was diagnosed NMOSD. OUTCOMES: Immunotherapy improved his peripheral neuropathy and myelitis symptoms. LESSONS: NMOSD patients could represent peripheral neuropathy as the first episode.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Process
[do] DOI:10.1097/MD.0000000000010059

  7 / 3178 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29514948
[Au] Autor:Cortese R; Magnollay L; Tur C; Abdel-Aziz K; Jacob A; De Angelis F; Yiannakas MC; Prados F; Ourselin S; Yousry TA; Barkhof F; Ciccarelli O
[Ad] Address:From the NMR Research Unit (R.C., L.M., C.T., F.D., M.C.Y., F.P., F.B., O.C.), Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, University College London; NMO Clinical Service at the Walton Centre (K.A.-A., A.J.), Liverpool; Translational Imaging G
[Ti] Title:Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD.
[So] Source:Neurology;, 2018 Mar 07.
[Is] ISSN:1526-632X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVE: To assess the value of the central vein sign (CVS) on a clinical 3T scanner to distinguish between multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). METHODS: Eighteen aquaporin-4-antibody-positive patients with NMOSD, 18 patients with relapsing-remitting MS, and 25 healthy controls underwent 3T MRI. The presence of a central vein in white matter lesions on susceptibility-weighted imaging, defined as a thin hypointense line or a small dot, was recorded. RESULTS: The proportion of lesions with the CVS was higher in MS than NMOSD (80% vs 32%, < 0.001). A greater proportion of lesions with the CVS predicted the diagnosis of MS, rather than NMOSD (odds ratio 1.10, 95% confidence interval [CI] 1.04 to 1.16, = 0.001), suggesting that each percent unit increase in the proportion of lesions with the CVS in an individual patient was associated with a 10% increase in the risk of the same patient having MS. If more than 54% of the lesions on any given scan show the CVS, then the patient can be given a diagnosis of MS with an accuracy of 94% (95% CIs 81.34, 99.32, < 0.001, sensitivity/specificity 90%/100%). CONCLUSION: The clinical value of the CVS in the context of the differential diagnosis between MS and NMOSD, previously suggested using 7T scanners, is now extended to clinical 3T scanners, thereby making a step towards the use of CVS in clinical practice. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that the CVS on 3T MRI accurately distinguishes patients with MS from those with seropositive NMOSD.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher

  8 / 3178 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29512413
[Au] Autor:Hyun JW; Huh SY; Shin HJ; Woodhall M; Kim SH; Irani SR; Lee SH; Waters P; Kim HJ
[Ad] Address:Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.
[Ti] Title:Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis.
[So] Source:Mult Scler;:1352458518761186, 2018 Mar 01.
[Is] ISSN:1477-0970
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVES: We aimed to evaluate the utility of the recently described brain lesion distribution criteria to differentiate multiple sclerosis (MS) from aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein immunoglobulin G-associated encephalomyelitis (MOG-EM) at disease onset in an Asian cohort. METHODS: A total of 214 patients who fulfilled the published criteria for MS, NMOSD, or MOG-EM and underwent brain magnetic resonance imaging (MRI) within 3 months of disease onset were enrolled. The brain lesion distribution criteria were defined as the presence of a lesion adjacent to the body of the lateral ventricle and in the inferior temporal lobe, or an S-shaped U-fiber lesion, or a Dawson's finger-type lesion. RESULTS: Brain lesions were identified in the initial MRI scans of 166/214 patients. The distribution criteria were applied to these scans (MS ( n = 94), NMOSD ( n = 64), and MOG-EM ( n = 8)). The sensitivity, specificity, and positive and negative predictive values of the criteria for MS versus NMOSD were 79.8%, 87.5%, 90.4%, and 74.7%, and for MS versus MOG-EM these were 79.8%, 100%, 100%, and 29.6%, respectively. CONCLUSION: These findings suggest that the brain lesion distribution criteria are helpful in distinguishing MS from NMOSD and MOG-EM in an Asian population, even at disease onset.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:Publisher
[do] DOI:10.1177/1352458518761186

  9 / 3178 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29511864
[Au] Autor:Tallantyre EC; Whittam DH; Jolles S; Paling D; Constantinesecu C; Robertson NP; Jacob A
[Ad] Address:University Hospital of Wales, Cardiff, UK.
[Ti] Title:Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.
[So] Source:J Neurol;, 2018 Mar 06.
[Is] ISSN:1432-1459
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:B-cell depleting anti-CD20 monoclonal antibody therapies are being increasingly used as long-term maintenance therapy for neuroinflammatory disease compared to many non-neurological diseases where they are used as remission-inducing agents. While hypogammaglobulinaemia is known to occur in over half of patients treated with medium to long-term B-cell-depleting therapy (in our cohort IgG 38, IgM 56 and IgA 18%), the risk of infections it poses seems to be under-recognised. Here, we report five cases of serious infections associated with hypogammaglobulinaemia occurring in patients receiving rituximab for neuromyelitis optica spectrum disorders. Sixty-four per cent of the whole cohort of patients studied had hypogammaglobulinemia. We discuss the implications of these cases to the wider use of anti-CD20 therapy in neuroinflammatory disease.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:Publisher
[do] DOI:10.1007/s00415-018-8812-0

  10 / 3178 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29478728
[Au] Autor:McGee JC; Minagar A
[Ad] Address:Department of Neurology, LSU Health Sciences Center, Shreveport 71130, LA, USA.
[Ti] Title:Neuromyelitis optica spectrum disorder in the very young: An in depth review of the present data.
[So] Source:J Neurol Sci;, 2018 Feb 17.
[Is] ISSN:1878-5883
[Cp] Country of publication:Netherlands
[La] Language:eng
[Pt] Publication type:EDITORIAL
[Em] Entry month:1802
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:Publisher


page 1 of 318 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information